Beyond Engagement: When Lived Experience Becomes Evidence

A recent article from Parexel on the evolving EU Health Technology Assessment (HTA) framework caught my attention. On the surface, it’s about patient and clinician engagement. Underneath, it’s about something much bigger: a redefinition of what counts as evidence.

For decades, patient engagement has largely existed alongside drug development. Sponsors conducted surveys. Researchers organized focus groups. Patient advocates were invited to advisory boards. Valuable work, but often disconnected from the evidence architecture itself.

What’s changing under the new EU HTA framework is that lived experience is increasingly being incorporated into decisions about endpoints, comparators, study design, and value assessment. Patients are no longer simply being asked for feedback. Their perspectives are becoming inputs into how evidence is generated and evaluated.

That is a meaningful step forward.

But it also raises an important question.

What if the future of patient evidence isn’t asking people what happened?

What if it’s understanding what is happening as it unfolds?

At Ember, we spend our days immersed in conversations from patients and caregivers navigating life with serious illness. Across thousands of longitudinal interactions in glioblastoma, we’ve observed something that traditional engagement methods often struggle to capture.

The most important barriers to care are frequently not clinical.

They’re the moments between clinic visits.

The caregiver who is exhausted but keeps pushing forward because there is no alternative.

The family trying to coordinate transportation to a specialist three hours away.

The spouse quietly taking over treatment decisions as cognitive decline progresses.

The patient who is interested in a clinical trial but becomes overwhelmed by the complexity of enrollment.

The daughter managing medications, insurance paperwork, work obligations, and childcare simultaneously.

These realities rarely appear neatly in a survey response.

They emerge naturally in conversation.

They reveal how disease affects daily life, how treatment decisions are actually made, and where participation begins to break down.

This is especially true in glioblastoma.

In many GBM families, the caregiver becomes one of the most important participants in the care journey. They research treatments, coordinate appointments, evaluate trial options, monitor symptoms, advocate within the healthcare system, and eventually make decisions on behalf of their loved one.

Yet much of our evidence ecosystem is still oriented around the patient alone.

If HTA bodies are serious about understanding treatment burden, quality of life, and real-world outcomes, caregiver experience can no longer be treated as a secondary consideration. It is often inseparable from the patient’s experience itself.

That is why I believe the next evolution goes beyond patient engagement.

It moves toward patient-derived evidence.

Not simply collecting opinions.

Observing patterns.

Understanding how burden accumulates.

Identifying the factors that influence participation, adherence, persistence, and decision-making before they become visible in traditional research methods.

A survey can tell us transportation is difficult.

Longitudinal conversations can show us when transportation becomes the reason an appointment is missed.

A focus group can tell us caregivers are stressed.

Longitudinal conversations can reveal when caregiver exhaustion begins affecting treatment decisions, clinical trial participation, or care continuity.

The distinction matters.

One describes a challenge.

The other helps explain its consequences.

As regulators, HTA organizations, and sponsors increasingly seek evidence that reflects real-world patient experience, the opportunity is not simply to hear more patient voices.

It is to understand the journey those voices are describing.

Because for many diseases, especially those involving progressive cognitive decline, the most important evidence may be hiding in plain sight—inside the daily decisions, frustrations, tradeoffs, and moments that never make it into a clinical record.

The future of patient-centered evidence is not just participation.

It’s observation.

It’s context.

It’s understanding what life with disease actually looks like when nobody is asking the questions.